Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (211-220 of 436) with videos related to

Pageof 44
Sort By:
International Journal of Hematology|March 5, 2019
Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitorsKoji Sasaki, Hagop M Kantarjian, Susan O'Brien, et al.
Leukemia & Lymphoma|November 10, 2017
Myeloid/lymphoid neoplasms with FGFR1 rearrangementPaolo Strati, Guilin Tang, Dzifa Y Duose, et al.
Journal of Hematology & Oncology|January 5, 2019
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experienceKamal Chamoun, Hagop Kantarjian, Rami Atallah, et al.
American Journal of Hematology|November 28, 2017
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expressionElias Jabbour, Johannes Düll, Musa Yilmaz, et al.
Leukemia|September 5, 2025
Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndromeAlexandre Bazinet, Guillermo Montalban-Bravo, Alex Bataller, et al.
Leukemia|March 28, 2023
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1Christopher P Mill, Warren Fiskus, Kaberi Das, et al.
Cancer|September 23, 2016
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemiaFarhad Ravandi, Jeffrey Jorgensen, Gautam Borthakur, et al.
Blood|January 6, 2016
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitorsPreetesh Jain, Hagop Kantarjian, Keyur P Patel, et al.
Blood Cancer Journal|March 18, 2021
Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II studyPatrick K Reville, Hagop M Kantarjian, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2023
Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic SyndromesSung-Eun Lee, Feng Wang, Maison Grefe, et al.
Pageof 44

Showing results (211-220 of 436) with videos related to

Sort By:
Pageof 44
International Journal of Hematology|March 5, 2019
Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitorsKoji Sasaki, Hagop M Kantarjian, Susan O'Brien, et al.
Leukemia & Lymphoma|November 10, 2017
Myeloid/lymphoid neoplasms with FGFR1 rearrangementPaolo Strati, Guilin Tang, Dzifa Y Duose, et al.
Journal of Hematology & Oncology|January 5, 2019
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experienceKamal Chamoun, Hagop Kantarjian, Rami Atallah, et al.
American Journal of Hematology|November 28, 2017
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expressionElias Jabbour, Johannes Düll, Musa Yilmaz, et al.
Leukemia|September 5, 2025
Impact of discordant revised versus molecular international prognostic scoring system risk in myelodysplastic syndromeAlexandre Bazinet, Guillermo Montalban-Bravo, Alex Bataller, et al.
Leukemia|March 28, 2023
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1Christopher P Mill, Warren Fiskus, Kaberi Das, et al.
Cancer|September 23, 2016
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemiaFarhad Ravandi, Jeffrey Jorgensen, Gautam Borthakur, et al.
Blood|January 6, 2016
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitorsPreetesh Jain, Hagop Kantarjian, Keyur P Patel, et al.
Blood Cancer Journal|March 18, 2021
Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II studyPatrick K Reville, Hagop M Kantarjian, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2023
Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic SyndromesSung-Eun Lee, Feng Wang, Maison Grefe, et al.
Pageof 44